Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer

Gene Therapy volume 17, pages 1325–1332 (2010)Cite this article

Subjects

Abstract

The sodium iodide symporter (NIS) directs the uptake and concentration of iodide in thyroid cells. We have extended the use of NIS-mediated radioiodine therapy to other types of cancer, we transferred and expressed the NIS gene into prostate, colon and breast cancer cells using adenoviral vectors. To improve vector efficiency we have developed a conditionally replicating adenovirus (CRAd) in which the E1a gene is driven by the prostate-specific promoter, Probasin and the cassette RSV promoter human NIScDNA-bGH polyA replaces the E3 region (CRAd Ad5PB_RSV-NIS). In vitro infection of the prostate cancer cell line LnCaP resulted in virus replication, cytolysis and release of infective viral particles. Conversely, the prostate cancer cell line PC-3 (androgen receptor negative) and the pancreatic cancer cell line Panc-1 were refractory to the viral cytopathic effect and did not support viral replication. Radioiodine uptake was readily measurable in LnCaP cells infected with Ad5PB_RSV-NIS 24 h post-infection, confirming NIS expression. In vivo, LnCaP tumor xenografts in nude-mice injected intratumorally with Ad5PB_RSV_NIS CRAd expressed NIS actively as evidenced by 99Tc uptake and imaging. Administration of therapeutic 131I after virus injection significantly increased survival probability in mice carrying xenografted LnCaP tumors compared with virotherapy alone. These data indicate that Ad5PB_RSV_NIS replication is stringently restricted to androgen-positive prostate cancer cells and results in effective NIS expression and uptake of radioiodine. This construct may allow multimodal therapy, combining cytolytic virotherapy with radioiodine treatment, to be developed as a novel treatment for prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J et al. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 1999; 20: 22–45.

    Article  CAS  Google Scholar 

  2. Chiocca EA, Broaddus WC, Gillies GT, Visted T, Lamfers ML . Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology. J Neuro-Oncol 2004; 69: 101–117.

    Article  Google Scholar 

  3. McCormick F . Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 2001; 1: 130–141.

    Article  CAS  Google Scholar 

  4. Yamamoto M, Curiel DT . Cancer gene therapy. Technol Cancer Res Treat 2005; 4: 315–330.

    Article  CAS  Google Scholar 

  5. Carrasco N . Iodide transport in the thyroid gland. Biochimica et Biophysica Acta 1993; 1154: 65–82.

    Article  CAS  Google Scholar 

  6. Jhiang SM, Cho JY, Ryu KY, DeYoung BR, Smanik PA, McGaughy VR et al. An immunohistochemical study of Na+/I- symporter in human thyroid tissues and salivary gland tissues. Endocrinology 1998; 139: 4416–4419.

    Article  CAS  Google Scholar 

  7. Van Nostrand D, Wartofsky L . Radioiodine in the treatment of thyroid cancer. Endocrinol Metabol Clinics North Am 2007; 36: 807–822.

    Article  Google Scholar 

  8. ELM. Carcinoma of follicular epithelium: Radioiodine and other treatments and outcomes. In: Braverman LE, Utiger RD (eds). The Thyroid: A Fundamental and Clinical Text, 7th ed. Lippincott: Raven, Philadelphia, 1996: 922–945.

  9. Scholz IV, Cengic N, Baker CH, Harrington KJ, Maletz K, Bergert ER et al. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Therapy 2005; 12: 272–280.

    Article  CAS  Google Scholar 

  10. Dwyer RM, Bergert ER, O’Connor MK, Gendler SJ, Morris JC . In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 2005; 11: 1483–1489.

    Article  CAS  Google Scholar 

  11. Dwyer RM, Bergert E R, O’Connor MK, Gendler SJ, Morris JC . Sodium Iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. Gene Therapy 2006; 13: 60–66.

    Article  CAS  Google Scholar 

  12. Spitzweg C, Dietz AB, O’Connor MK, Bergert ER, Tindall DJ, Young CY et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Therapy 2001; 8: 1524–1531.

    Article  CAS  Google Scholar 

  13. Dwyer RM, Schatz SM, Bergert ER, Myers RM, Harvey ME, Classic KL et al. A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. Mol Ther: J Am Soc Gene Ther 2005; 12: 835–841.

    Article  CAS  Google Scholar 

  14. Morris JC . 〈http://clinicaltrials.gov/ct/show/NCT00788307〉 2009.

  15. Herrmann F . Cancer gene therapy: principles, problems, and perspectives. J Mol Med 1995; 73: 157–163.

    CAS  PubMed  Google Scholar 

  16. Waehler R, Russell SJ, Curiel DT . Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007; 8: 573–587.

    Article  CAS  Google Scholar 

  17. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373–376.

    Article  CAS  Google Scholar 

  18. Markert JM, Malick A, Coen DM, Martuza RL . Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 1993; 32: 597–603.

    Article  CAS  Google Scholar 

  19. Russell SJ . RNA viruses as virotherapy agents. Cancer Gene Ther 2002; 9: 961–966.

    Article  CAS  Google Scholar 

  20. Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD et al. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Hum Gene Ther 2008; 19: 873–886.

    Article  CAS  Google Scholar 

  21. Chu RL, Post DE, Khuri FR, Van Meir EG . Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004; 10: 5299–5312.

    Article  CAS  Google Scholar 

  22. Dingli D, Peng KW, Harvey ME, Greipp PR, O’Connor MK, Cattaneo R et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103: 1641–1646.

    Article  CAS  Google Scholar 

  23. Zhang J, Thomas TZ, Kasper S, Matusik RJ . A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000; 141: 4698–4710.

    Article  CAS  Google Scholar 

  24. Zuckier LS, Dohan O, Li Y, Chang CJ, Carrasco N, Dadachova E . Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo. J Nuclear Med 2004; 45: 500–507.

    CAS  Google Scholar 

  25. Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM, Morris JC . Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res 2003; 63: 7840–7844.

    CAS  PubMed  Google Scholar 

  26. Cascallo M, Capella G, Mazo A, Alemany R . Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res 2003; 63: 5544–5550.

    CAS  PubMed  Google Scholar 

  27. Humphreys MJ, Greenhalf W, Neoptolemos JP, Ghaneh P . The potential for gene therapy in pancreatic cancer. Int J Pancreatol 1999; 26: 5–21.

    Article  CAS  Google Scholar 

  28. Hung MC, Hortobagyi GN, Ueno NT . Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. Adv Exp Med Biol 2000; 465: 171–180.

    Article  CAS  Google Scholar 

  29. Miura Y, Ohnami S, Yoshida K, Ohashi M, Nakano M, Fukuhara M et al. Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity. Cancer Lett 2005; 218: 53–62.

    Article  CAS  Google Scholar 

  30. Young LS, Searle PF, Onion D, Mautner V . Viral gene therapy strategies: from basic science to clinical application. J Pathol 2006; 208: 299–318.

    Article  CAS  Google Scholar 

  31. Schmidt-Wolf G, Schmidt-Wolf IG . Human cancer and gene therapy. Ann Hematol 1994; 69: 273–279.

    Article  CAS  Google Scholar 

  32. Kaminsky SM, Levy O, Salvador C, Dai G, Carrasco N . The Na+/I- symporter of the thyroid gland. Soc Gen Physiol Ser 1993; 48: 251–262.

    CAS  PubMed  Google Scholar 

  33. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001; 19: 3422–3433.

    Article  CAS  Google Scholar 

  34. Ricciardelli C, Jackson MW, Choong CS, Stahl J, Marshall VR, Horsfall DJ et al. Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate 2008; 68: 830–838.

    Article  CAS  Google Scholar 

  35. Qu CF, Li Y, Song YJ, Rizvi SM, Raja C, Zhang D et al. MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595radioimmunoconjugate. Br J Cancer 2004; 91: 2086–2093.

    Article  CAS  Google Scholar 

  36. Anderson RD, Haskell R E, Xia H, Roessler BJ, Davidson BL . A simple method for the rapid generation of recombinant adenovirus vectors. Gene Therapy 2000; 7: 1034–1038.

    Article  CAS  Google Scholar 

  37. Weiss SJ, Philp NJ, Grollman EF . Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology 1984; 114: 1090–1098.

    Article  CAS  Google Scholar 

  38. Spitzweg C, Dietz AB, O’Connor MK, Bergert ER, Tindall DJ, Young CY et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Therapy 2001; 8: 1524–1531.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Azhal Ahmadi, Robert Parrish, Rachel E Carlson, Tracy Decklever and Dr Jian Qiao for technical help. This work was supported by Prostate SPORE Grant P50 CA 091956, Donald J Tindall, PI, John C Morris, Project Director.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Endocrinology, Diabetes, Metabolism, Nutrition, Mayo Clinic, Rochester, MN, USA

    M A Trujillo, S McDonough & J C Morris

  2. Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA

    M J Oneal

  3. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA

    R Qin

Authors
  1. M A Trujillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M J Oneal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S McDonough
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J C Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J C Morris.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trujillo, M., Oneal, M., McDonough, S. et al. A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer. Gene Ther 17, 1325–1332 (2010). https://doi.org/10.1038/gt.2010.63

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gt.2010.63

Keywords

This article is cited by

Search

Advanced search

Quick links